Literature DB >> 27321737

Yes, We Still Need IL-2 Receptor Antagonists.

J N Fleming1, D J Taber2,3, N A Pilch4, T R Srinivas5, K D Chavin2.   

Abstract

Keywords:  Immunosuppressant; editorial/personal viewpoint; fusion proteins and monoclonal antibodies: basiliximab/daclizumab; immunosuppressant; immunosuppressive regimens; induction; kidney transplantation/nephrology; polyclonal preparations: rabbit antithymocyte globulin

Mesh：

Substances：

Year:  2016        PMID： 27321737     DOI： 10.1111/ajt.13930

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  2 in total

Review 1.  State-of-the-art immunosuppression protocols for pediatric renal transplant recipients.

Authors:  Lars Pape
Journal:  Pediatr Nephrol       Date:  2017-10-24       Impact factor: 3.714

2.  Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic.

Authors:  Sunjae Bae; Mara A McAdams-DeMarco; Allan B Massie; JiYoon B Ahn; William A Werbel; Daniel C Brennan; Krista L Lentine; Christine M Durand; Dorry L Segev
Journal:  Transplantation       Date:  2021-01-01       Impact factor: 5.385
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.